Role of Shigella flexneri 2a 34 kDa outer membrane protein in induction of protective immune response

Vaccine

Volumn 24, Issue 33-34, 2006, Pages 6028-6036

  Mukhopadhaya, A ^a   Mahalanabis, D ^b   Chakrabarti, M K ^a  

^a NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

^b SOCIETY FOR APPLIED STUDIES   (India)

Author keywords

Outer membrane proteins; Shigella vaccine; Shigellosis

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 12; NITRIC OXIDE; OUTER MEMBRANE PROTEIN; SHIGELLA VACCINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL OUTER MEMBRANE; BACTERIAL VIRULENCE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; FEMALE; IMMUNE RESPONSE; MACROPHAGE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; SHIGELLA FLEXNERI; SHIGELLOSIS; STATISTICAL SIGNIFICANCE; TH1 CELL;

ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DYSENTERY, BACILLARY; FEMALE; INTERLEUKIN-10; INTERLEUKIN-12; MACROPHAGES, PERITONEAL; MALE; MICE; NITRIC OXIDE; RABBITS; SHIGELLA FLEXNERI; SHIGELLA VACCINES; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, SUBUNIT;

EID: 33746545105     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.03.026     Document Type: Article

References (36)

1. Dan M., Michaeli D., and Triestman J. The epidemiology of shigellosis in Israel. Am Trop Med Parasitol 82 (1988) 159-162
2. Du Pont H.L., Olarte J., and Evans D.G. Comparative susceptibility of Latin American and United States students to enteric pathogens. N Engl J Med 285 (1976) 1520-1521
3. Echeveriia P., Sethabutr O., Serichantelergs O., Lexomboon U., and Tamura K. Shigella and enteroinvasive Escherichia coli infections in households of children with dysentery in Bangkok. J Infect Dis 16 (1992) 144-147
4. Ghosh A.R., and Sehgal S.C. Existing status of shigellosis in Andaman. Existing status of shigellosis in Andaman & Nicobar Islands. Indian J Med Res 103 (1996) 134-137
5. Green M.S., Block C., Cohen D., and Slater P. Four decades of shigellosis in Israel-the epidemiology of a growing public health problem. Rev Infect Dis 13 (1991) 248-253
6. Hyams K.C., Bourgeois A.L., Merrell B.R., Rozmajzl P., Escamilla J., Thornton S.A., et al. Diarrhoeal disease during operation deserts shield. N Engl J Med 325 (1991) 1423-1428
7. Parry J., Duggal H., Beaumont M., Jeckinson H., and Price C. A report of an outbreak of shigellosis in a primary school in Staffordshire. Pub. Health 115 (2001) 295-300
8. Thomson A.W. The cytokine handbook. 3rd ed. (1998), Academic Press, San Diego, California
9. Garcia-Fulgueiras A., Sanchez S., Guillen J.J., Marsillia B., Aladuena A., and Navarro C. A large outbreak of Shigella sonnei gastroenteritis associated with consumption of fresh pasteurized milk cheese. Eur J Epidemiol 17 (2001) 533-538
10. Diarrhoeal disease due to Shigella in vaccines. Immunization and biologicals. Website (http://www.who.int/vaccines/en/shigella.shtml) of World Health Organization updated on May 2002.
11. Ashkenazi S., Levy I., Kazaronovsky V., and Samra Z. Growing antimicrobial resistance of Shigella isolates. J Antimicrob Chemother 51 (2003) 427-429
12. Sarkar K., Ghosh S., Niyogi S.K., and Bhattacharya S.K. Shigella dysenteriae type 1 with reduced susceptibility to fluoroquinolones. Lancet 361 (2003) 785
13. Taylor D.N., Echeverria P., Pál T., Sethabutr O., Saiborisuth S., Sricharmorn S., et al. The role of Shigella spp., enteroinvasive Escherichia coli, and other enteropathogens as causes of childhood dysentery in Thailand. J Infect Dis 153 (1986) 1132-1138
14. Canada communicable disease report (CCDR). Shigella vaccine research and development, vol 23-08. 1997.
15. Sansonetti P.J., Egile C., and Wemmerias C. Shigellosis from disease symptoms to molecular and cellular pathogenesis (2001), Academic Press, New York pp. 336-385
16. Anders K., Li A., Zhao C.R., Karlsson K., Minh N.B., and Lindberg A.A. Safety and immunogenicity of the auxotrophic Shigella flexneri 2a vaccine SFL1070 with a deleted aroD gene in adult Swedish volunteers. Vaccine 13 (1995) 88-89
17. Coster T.S., Charles H.W., Lillian L., VanDeVerg A., Hartman A.B., Oaks E.V., et al. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immunol 67 (1999) 3437-3443
18. Katz D.E., Coster T.S., Wolf M.K., Trespalacios F.C., Cohen D., Robins G., et al. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect Immunol 72 (2004) 923-930
19. Kotloff K.L., Noriega F., Losonsky G.A., Sztein M.B., Wasserman S.S., Nataro J.P., et al. Safety, immunogenicity, and transmissibility in humans of cvd 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. Infect Immunol 64 (1996) 4542-4548
20. Noriega F.R., Losonsky G., Lauderbaugh C., Liao F.M., Wang J.Y., and Levine M.M. Engineered ΔguaB-A ΔvirG Shigella flexneri 2a strain CVD 1205: construction safety and immunogenicity, and potential efficacy as a mucosal vaccine. Infect Immunol 64 (1996) 3055-3061
21. Passwell J.H., Harlev E., Ashkenazi S., Chu C., Miron D., Ramon R., et al. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel. Infect Immunol 69 (2001) 1351-1357
22. Ranallo R.T., Fonseka C.P., Cassels F., Srinivasan J., and Venkatesan M.M. Construction and characterization of bivalent Shigella flexneri 2a vaccine strains SC608(pCFAI) and SC608(pCFAI/LTB) that express antigens from enterotoxigenic Escherichia coli. Infect Immunol 73 1 (2005) 258-267
23. Mukhopadhaya A., Mahalanabis D., Khanam J., and Chakrabarti M.K. Protective efficacy of oral immunization with heat-killed Shigella flexneri 2a in animal model: study of cross protection, immune response and antigenic recognition. Vaccine 21 (2003) 3043-3050
24. Chakrabarti M.K., Bhattacharya J., Nair G.B., Bhattacharya S.K., and Mahalanabis D. Killed oral Shigella vaccine made from Shigella flexneri 2a protects against challenge in the rabbit model of shigellosis. Acta Paediatr 87 (1998) 1-5
25. Filip C., Fletcher G., Wullf J.L., and Earhart C.F. Solubilization of the cytoplasmic membrane Escherichia coli by the ionic detergent sodium lauryl sarcosinate. J Bacteriol 115 (1973) 717-722
26. Markwell M.A.K., Haas S.M., Beilur L.L., and Tolbert N.E. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 87 (1978) 206-210
27. Laemmli U.K. Change of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
28. Sengupta D.K., Sengupta T.K., and Ghose A.C. Major outer membrane proteins of Vibrio cholerae and their role in induction of protective immunity through inhibition of intestinal colonization. Infect Immunol 60 (1992) 4848-4855
29. Rabbani G.H., Albert M.J., Rahman H., Kabir I., Alam K., and Ansaruzzaman M. Development of an improved animal model of shigellosis in the adult rabbit by colonic infection with Shigella flexneri 2a. Infect Immunol 63 (1995) 4360-4367
30. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantitites of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
31. Biswas T. Role of porin of Shigella dysenteriae type 1 in modulation of lipopolysaccharide mediated nitric oxide and interleukin-1 release by murine peritoneal macrophages. FEMS Immunol Med Microbiol 29 (2000) 129-136
32. Towbin H., Steeling T., and Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76 (1979) 4350-4354
33. Bogdan C., Röllinghoff M., and Diefenbach A. The role of nitric oxide in innate immunity. Immunol Rev 173 (2000) 17-26
34. Krakauer T., Vileck J., and Oppenheim J.J. In: Paul W.E. (Ed). Fundamental immunology (1999), Lippincott-Raven, Philadelphia 775-811
35. Haddad D., Liljeqvist S., Kumar S., Hansson M., Stahl S., Perlmann H., et al. Surface display compared to periplasmic expression of a malarial antigen in Salmonella typhimurium and its implications for immunogenicity. FEMS Immunol Med Microbiol 12 (1995) 175-186
36. Jeannin P., Renno T., Goetsch L., Miconnet I., Aubry J.P., Delneste Y., et al. OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway. Nat Immunol 1 (2000) 502-509